Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer

March 20, 2009

Washington, DC - New research suggests that monoclonal antibody therapy of cancer can be improved to be much more powerful than it is today, says a researcher at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center in the March 21 issue of the Lancet.

"We believe that antibody therapy has the capacity to immunize people against cancer," says Louis Weiner, MD, director of the cancer center at GUMC and an internationally recognized expert in development and use of monoclonal antibodies. "Treatment modifications might be able to prolong, amplify, and shape a continuous immune response to cancer cells."

Weiner was asked by Lancet editors to write a review article discussing the newest research in this field. His co-authors are Madhav Dhodapkar, MD, of Yale University and Soldano Ferrone, MD, of the University of Pittsburgh.

Their analysis, based on reviewing the last eight years of research on monoclonal antibody treatment, suggests that a new era in use of these therapies is just around the corner. "Scientists have been able to use new tools to measure effectiveness of these therapies, and have found that antibodies are capable of stimulating the immune system in ways that had not been appreciated to date, and which we can now take advantage of," Weiner says.

Antibodies are immune system proteins that seek out and neutralize molecules they recognize as foreign to a body, such as viruses and bacteria. Monoclonal antibodies are proteins crafted in a laboratory to recognize specific receptors, or antigens, on cancer cells; some antigens promote uncontrolled growth. These antibodies are designed to both attach to cancer receptors to inhibit their function and to alert and activate the immune system to the presence of these receptor proteins.

Monoclonal antibodies already offer effective treatment for a wide range of cancers, including breast cancer (Herceptin®, Avastin®), colorectal cancer (Erbitux®, Avastin), lung cancer (Avastin), and blood cancers (Rituxan®, Campath®), but they have appeared to primarily work by forcing tumor related receptors to shut down pro-growth signals, Weiner says.

"For years it has been presumed that the ability of antibodies to interfere with malignant cell-related signaling is the dominant mechanism of anticancer activity, but we have also known that the normal job of an antibody is to deliver an antigen to the body's immune system which then destroys the target," Weiner says.

Recent research by Weiner and others, however, now shows that antibodies can inhibit function not only as signaling manipulators but also as initiators of immune responses that leads to control of cancer, the authors say.

"We believe that Herceptin and Rituxan, as examples, work in part by immunizing people against cancer, but at this point, the magnitude of that response is variable and is frequently very small," Weiner says.

Scientists now believe that it will be possible to alter the antibodies so that they induce both kinds of human immunity - the innate immune response that is short-lasting and which directly kills tumor cells, and a long-lasting "memory" response that comes from the adaptive immune response. "We have long thought that monoclonal antibodies are capable of stimulating the innate immune system, but we now have evidence that the therapy can prime an adaptive response as well. Such responses would make the treatment much more powerful, capable of keeping cancer under control," he says.

"For the first time we are using technology that can measure the immune response that is occurring in monoclonal antibody treatment, and which will help us build better antibodies that amplify and shape that immune response to become more powerful," Weiner says.

And in the future, it may be possible to build antibodies that are targeted to existing targets on a patient's tumor, as well as to targets that may appear as the cancer mutates. "This one-two punch would anticipate how the tumor changes over time and cut off the cancer's escape route," Weiner says. "These new directions are very exciting."

Georgetown University Medical Center

Therapeutic Monoclonal Antibodies: From Bench to Clinic
by Zhiqiang An (Editor)

70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. First book to address the discovery and development of antibody therapeutics in their entirety.Most chapters contain experimental data to illustrate the principles described in them.Authors provide detailed methodologies that readers can take away with them and use in their own laboratories

Monoclonal Antibodies, Third Edition: Principles and Practice
by James W. Goding (Author)

Monoclonal Antibodies now have applications in virtually all areas of biology and medicine, and much of the world's biotechnology industry has its foundations in the exploitation of this technology.
The Third Edition of this well established book meets the needs of both newcomers to the area and experienced researchers, by providing an integrated treatment of both the production and application of monoclonal antibodies. As in previous editions, detailed and critical accounts of the theory, production, purification, fragmentation, storage and radiolabelling of monoclonal antibodies are given, along with descriptions of their use in antigen characterization, affinity chromatography and immunofluorescence. The present volume has been comprehensively updated to cover recent rapid advances,...

Monoclonal Antibodies: Methods and Protocols (Methods in Molecular Biology)
by Maher Albitar (Editor)

This book examines a collection of state-of-the-art methods that employ monoclonal antibodies in a clinical setting. The chapters offer in-depth description for generating mouse and recombinant humanized antibodies, and a comprehensive review of how antibodies are being used in bead-based methods for measuring proteins. This field will continue to expand and provide new and innovative techniques in the laboratory and as a basis that complements targeted therapy.

Current Trends in Monoclonal Antibody Development and Manufacturing (Biotechnology: Pharmaceutical Aspects)
by Steven J. Shire (Editor), Wayne Gombotz (Editor), Karoline Bechtold-Peters (Editor), James Andya (Editor)

Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade. Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER...

Process Scale Purification of Antibodies
by Uwe Gottschalk (Editor)

Traditional column chromatography dominates current purification technology, and many of the productivity gains that have been achieved have relied on upscaling such devices. However, this comes with a cost penalty and the pharmaceutical industry has reached the point at which further upscaling becomes economically unsupportable. This book offers a broad-based reassessment of old and new purification methods, incorporating an analysis of innovative new trends in purification. The book has wide coverage of different antibody purification strategies and brings together top-tier experts to address problems in process-scale antibody purification.

A Practical Guide to Monoclonal Antibodies
by J. Eryl Liddell (Author), A. Cryer (Author)

Includes all of the information required to produce monoclonal antibodies in the laboratory and to prepare them for use in a multitude of given applications. Production procedures are treated in chronological order, beginning with basic tissue culture techniques, immunization strategies and screening test design, followed by production of hybridoma cell lines and basic antibody characterization, purification and labeling. Each chapter contains explanatory text on each step with comparative analysis of methods where appropriate. All necessary experimental protocols are presented in a self-contained format that is easy to follow in the laboratory. Alternative protocols are provided where relevant; for others not included in full, source references are presented. Surveys the current status...

Monoclonal Antibodies: A Practical Approach (Practical Approach Series)
by Christopher Dean (Author), Philip Shepherd (Editor)

Monoclonal Antibodies: A Practical Approach covers the preparation, testing, derivation, and applications of monoclonal antibodies. New immunological techniques incorporating tried and tested methodologies are described, making the book of interest to established and inexperienced immunologists. Both the standard somatic hybridization technique and recombinant techniques, including the use of phage libraries, for the preparation of rodent and human monoclonal antibodies are described. Protocols for both the small and large scale production are detailed, as well as purification and labelling (with both radioisotopes and non-radioisotopes) methods. The applications of monoclonal antibodies in immunoblotting, enzyme linked immunoassays, immunofluorescence, and FACS analysis are all covered...

Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer
by Raymond M. Reilly (Editor)

Oncology Book of 2011, British Medical Association's Medical Book AwardsAwarded first prize in the Oncology category at the 2011 BMA Medical Book Awards, Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this hot pharmaceutical field with up-to-date developments. Expert discussion covers a range of diverse topics associated with this field, including the optimization of design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from key clinical trials, radiation biology and dosimetry, and considerations in regulatory approval. With chapters authored by internationally renowned experts, this book delivers a wealth of information to push future discovery.

Cancer Diagnosis in Vitro Using Monoclonal Antibodies (Immunology Series)
by Herbert Z. Kupchik (Editor)

Antibody Phage Display: Methods and Protocols (Methods in Molecular Biology)
by Robert Aitken (Editor)

Since its introduction almost 20 years ago, phage display technology has revolutionized approaches to the analysis of biomedical problems, quickly impacting the fields of immunology, cell biology, biotechnology, pharmacology, and drug discovery. In Antibody Phage Display: Methods and Protocols, Second Edition, expert researchers explore the latest in this cutting-edge technology, providing an invaluable resource that will guide readers in the design and execution of experiments based around antibody phage display. Chapters present a wide range of methods of isolating recombinant antibodies from phage display libraries, examine how the targets recognized by antibodies of interest can be identified, discuss the identification and exploitation of antibodies that can enter cells and bind to...